NEW YORK (GenomeWeb News) – Rosetta Genomics said after the close of the market on Monday that its revenues for 2013 more than doubled year over year.

The microRNA-based diagnostics firm said that revenues last year increased to $405,000 from $201,000 in 2012 as commercial activities and investments in its commercial infrastructure ticked up.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.